caa a22 4500 469073748 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF01756190 doi (NATIONALLICENCE)springer-10.1007/BF01756190 Lymphokine production by human melanoma tumor-infiltrating lymphocytes [Elektronische Daten] [Marie Salmeron, Tatsuo Morita, Hidetoshi Seki, Chris Platsoucas, Kyogo Itoh] Summary: Lymphokine production by human melanoma tumor-infiltrating lymphocytes (TIL) was studied. Uncultured TIL produced interferon γ (IFNγ), but not interleukin-2 (IL-2) or IL-4, in response to anti-CD3 mAb or IL-2. In bulk cultures, IL-2-activated TIL displaying autologous tumor-specific cytotoxicity (CTL-TIL) produced IFNγ in culture with medium alone, whereas IL-2-activated noncytotoxic TIL did not. Addition of anti-CD3 mAb or autologous tumor cells up-regulated IFNγ production in IL-2-activated TIL from 10 of 12 or 6 of 12 cases respectively. Those from 4 of 12 cases (2 CTL-TIL and 2 noncytotoxic TIL) produced IL-2 in culture with medium alone. At the clonal level, 5 (4 CD4+ and 1 CD8+) of 7 autologous tumor-specific CTL clones derived from TIL and 3 (2 CD4+ and 1 CD8+) of 7 noncytotoxic TIL clones produced IFNγ in culture with medium alone, which was up-regulated by adding anti-CD3 mAb. Two IFNγ-producing CTL clones tested produced IL-2 in 4 ×-concentrated supernatants from a 3.5-h culture with medium alone. Furthermore, 2 IFNγ-producing CTL clones tested expressed mRNA for both IFNγ and IL-2. IL-2 production and its mRNA expression were up- or down-regulated, respectively, by adding anti-CD3 mAb or autologous tumor cells. IL-4 production was not observed in culture either with medium alone or with IL-2 in any of the cells described above. Anti-CD3 mAb was required for IL-4 production in 3 of 12 IL-2-activated TIL, 2 of 6 CTL clones, and none of 5 noncytotoxic TIL clones. In summary, IFNγ production was characteristic of melanoma TIL. Some autologous tumor-specific CTL in TIL are suggested to be productive of IL-2 and IFNγ under unstimulated conditions, both being required for self-activation in an autocrine loop. Springer-Verlag, 1992 Tumor-infiltrating lymphocytes nationallicence Melanoma nationallicence Lymphokine production nationallicence Salmeron Marie Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut Morita Tatsuo Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut Seki Hidetoshi Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut Platsoucas Chris Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut Itoh Kyogo Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 35/3(1992-05-01), 211-217 0340-7004 35:3<211 1992 35 262 https://doi.org/10.1007/BF01756190 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01756190 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Salmeron Marie Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Morita Tatsuo Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Seki Hidetoshi Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Platsoucas Chris Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Itoh Kyogo Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, 77 030, Houston, Texas, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/3(1992-05-01), 211-217 0340-7004 35:3<211 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer